The Pfizer-BioNTech COVID-19 vaccine was 73 % efficient in
defending youngsters ages 6 months by way of 4 years throughout the time
when the Omicron pressure was extremely prevalent, Pfizer introduced,
Pattern stories citing Xinhua.
The vaccine was granted Emergency Use Authorization by the U.S.
Meals and Drug Administration for this age group on June 17.
Individuals within the examine acquired both three 3-µg doses of
Pfizer-BioNTech vaccine or placebo. Vaccine efficacy was 73.2
% amongst youngsters 6 months by way of 4 years of age with out
proof of prior COVID-19 an infection, in accordance with the outcomes
introduced by the 2 firms.
“Whereas these outcomes affirm that three 3-µg doses of our
COVID-19 vaccine present younger youngsters with a excessive degree of
safety at a time when the Omicron BA.2 pressure was extremely
prevalent with a good security profile, we’re additionally growing
an Omicron BA.4/BA.5-adapted bivalent vaccine on this age group to
handle these sublineages,” stated Ugur Sahin, CEO and Co-Founding father of
BioNTech.
